Search
Filter Results
Displaying 171–180 of 543 for “Retinitis pigmentosa”
-
Support your clients’ charitable giving with the Foundation Fighting Blindness—where tax-smart donations fund breakthrough medical research.
-
Oct 2, 2025
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Sep 26, 2025
Eye on the Cure Podcast | Episode 92: Lance Baldo, MD
Eye on the CureLance Baldo, MD, CEO at Beacon Therapeutics, is discussing his company’s gene therapy for XLRP.
-
Sep 17, 2025
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
Advocacy Research NewsOn behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Aug 25, 2025
Beacon StoriesLindsey Rambo once believed treatment was meant for someone else. Today, she’s the first participant in a groundbreaking gene therapy trial for LCA5—and her journey is lighting the way for what’s possible in the future of vision research.
-
Aug 20, 2025
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
-
Aug 19, 2025
Invisible DisabilityWhen I walk around the neighborhood with my white cane, I still worry about stigma and how people perceive me. I’ve had to remind myself that the cane is a tool to keep me safe.
-
Jul 14, 2025
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Research NewsThe company plans to complete BLA submission in early 2026.
-
Jul 11, 2025
Eye on the Cure Podcast | Episode 88: Richard Small
Eye on the CureRichard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
-
VISIONS 2026: United in Vision Schedule
The United in Vision 2026 conference unites two prestigious events—the Foundation Fighting Blindness VISIONS conference and the Retina International World Congress—into one extraordinary global gathering. Scheduled from Wednesday, June 10 to Saturday, June 13, 2026, at the Fort Worth Convention Center in Fort Worth, Texas,